Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cetuximab and radiotherapy for head and neck cancer.

× No keyword cloud information.

10 in total

Review 1. [Update on HPV-induced oropharyngeal cancer].

Authors: S F Preuss; J-P Klussmann; R Semrau; C Huebbers
Journal: HNO Date: 2011-10 Impact factor: 1.284

Review 2. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.

Authors: Christian Freudlsperger; Jeffrey R Burnett; Jay A Friedman; Vishnu R Kannabiran; Zhong Chen; Carter Van Waes
Journal: Expert Opin Ther Targets Date: 2010-11-26 Impact factor: 6.902

Review 3. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

Authors: James E Frampton
Journal: Drugs Date: 2010-10-22 Impact factor: 9.546

4. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.

Authors: Marina Cardó-Vila; Ricardo J Giordano; Richard L Sidman; Lawrence F Bronk; Zhen Fan; John Mendelsohn; Wadih Arap; Renata Pasqualini
Journal: Proc Natl Acad Sci U S A Date: 2010-02-26 Impact factor: 11.205

Review 5. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.

Authors: Stephanie K A Blick; Lesley J Scott
Journal: Drugs Date: 2007 Impact factor: 9.546

6. A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.

Authors: G C MacDonald; M Rasamoelisolo; J Entwistle; W Cuthbert; M Kowalski; Maureen A Spearman; N Glover
Journal: Med Oncol Date: 2008-10-28 Impact factor: 3.064

7. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Authors: Glen C MacDonald; Michèle Rasamoelisolo; Joycelyn Entwistle; Jeannick Cizeau; Denis Bosc; Wendy Cuthbert; Mark Kowalski; Maureen Spearman; Nick Glover
Journal: Drug Des Devel Ther Date: 2009-02-06 Impact factor: 4.162

8. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Authors: M G Fury; E J Sherman; S S Rao; S Wolden; S Smith-Marrone; B Mueller; K K Ng; P R Dutta; D Y Gelblum; J L Lee; R Shen; S Kurz; N Katabi; S Haque; N Y Lee; D G Pfister
Journal: Ann Oncol Date: 2014-02-03 Impact factor: 32.976

9. Transoral treatment strategies for head and neck tumors.

Authors: Christoph Arens
Journal: GMS Curr Top Otorhinolaryngol Head Neck Surg Date: 2012-12-20

10. EGFR expression in gallbladder carcinoma in North America.

Authors: Matthew Kaufman; Bhoomi Mehrotra; Sewanti Limaye; Sherrie White; Alexander Fuchs; Yehuda Lebowicz; Sandy Nissel-Horowitz; Adrienne Thomas
Journal: Int J Med Sci Date: 2008-09-22 Impact factor: 3.738

10 in total